Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979026 | 0.91 | TRPV1 (0.45) | KMT2AP2RY12GABRA5NPC1RAB9A | |
| SCHEMBL3975360 | 0.91 | NPC1 (0.48) | KMT2AP2RY12GABRA5NPC1RAB9A | |
| SCHEMBL3976838 | 0.90 | GABRA5 (0.51) | KMT2AP2RY12GABRA5NPC1RAB9A | |
| SCHEMBL3979034 | 0.88 | GABRA5 (0.51) | KMT2AP2RY12GABRA5 | |
| SCHEMBL3979100 | 0.84 | NPSR1 (0.60) | P2RY12GABRA5USP2L3MBTL1HTT | |
| SCHEMBL13842556 | 0.83 | GABRA5 (0.45) | KMT2AGABRA5HTT | |
| SCHEMBL3978337 | 0.82 | KMT2A (0.54) | KMT2AP2RY12USP2LMNAHTT | |
| SCHEMBL27715445 | 0.82 | KMT2A (0.47) | KMT2AP2RY12GABRA5USP2LMNA | |
| SCHEMBL5535276 | 0.80 | KMT2A (0.62) | KMT2AGABRA5L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL4248633 | 0.80 | HTT (0.61) | KMT2AGABRA5NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1931661-B1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| CN-101263139-A | Isoxazolo derivatives as GABA A alpha5 inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066668-A1 | Isoxazolo derivatives | GABRA5, GABRA4, GABRA1 | KMT2A 2468/4885P2RY12 517/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.